Primitive hematopoietic cells released into the peripheral blood (PB) were studied in 50 patients with high-grade non-Hodgkin's lymphoma enrolled in a phase 111 trial of intensive weekly chemotherapy (VAPEC-6) alone or with granulocyte colony-stimulating factor (G-CSF). Mononuclear cells numbers were monitored and their in vitro growth potential assessed in clonogenic progenitor cell assays and in long-term culture. Total colony-forming cells (granulocyte-macrophage [GM], burst-forming unit, erythroid [BFU-E], Mix-CFC) were increased 40-fold (median) over baseline with chemotherapy alone and 106-fold with chemotherapy and G-CSF after the final dose. CD34' cells were increased to a median of 4%. equivalent to that in normal bone marrow (BM) controls. Circulating colonyforming cell levels were maximal when the recovering total white blood cell (WBC) count reached 5 to 10 X 1 09/L. The timing of the maximum was reproducible in individual patients. Therefore the WBC count can be used as a guide
HE INTRODUCTION of combination cytotoxic che-
T motherapy dramatically improved the outlook for patients with high-grade non-Hodgkin's lymphoma (NHL), but many patients still die of their disease. Retrospective studies suggest that increased cytotoxic dose intensity correlates with response rate and survival in patients with highgrade NHL.'.' In acute leukemia, myeloablative therapy with bone marrow (BM) transplantation has become part of the established treatment. A recent randomized study of high-dose therapy with BM transplantation versus conventional consolidation chemotherapy for relapsed and resistant Hodgkin's disease was closed prematurely because there was a better relapse-free survival in the transplantation group and later patients refused rand~mization.~ In NHL, patients with poor prognosis can be identified by scoring adverse factors at pre~entation.~ For this group, myeloablative chemotherapy and hemopoietic rescue are increasingly used in an attempt to improve relapse-free and overall However, the extension of such controversial and intensive treatment strategies to a wider range of patients, including those in first remission, demands that treatment-related morbidity and mortality are minimized.
A promising new approach to giving high-dose therapy more safely involves hematopoietic rescue with mononuclear cells harvested from peripheral blood (PB). In addition to its feasibility in patients with BM involvement or previous radiotherapy, PB progenitor cell transplantation offers practical advantages over autologous BM transplantation. These include a shorter time to platelet recovery (and independence from platelet transfusions) and earlier neutrophil recovery.*-' ' Normal PB contains few primitive cells (hemopoietic progenitors and stem cells) compared with BM.",'' Large volumes of normal blood need to be apheresed to obtain sufficient stem cells for hematopoietic rescue after myeloablative therapy. Furthermore, their capacity to regenerate hematopoiesis is poor compared with that of BM.l3, I4 Recently, the problem oflow numbers ofcirculating primitive cells has been overcome by collection of blood cells to the timing of leukapheresis. PB cells from normal controls' and patients' prechemotherapy were unable to sustain hemopoiesis in two-stage long-term cultures. In contrast, PB cells collected from patients primed with chemotherapy alone or chemotherapy with G-CSF at the time of predicted maximal colony-forming cell release were able to generate and sustain hematopoiesis in longterm cultures at a level comparable or superior to normal BM. These findings indicate that the use of G-CSF after routine outpatient chemotherapy stimulates maximal release of primitive hemopoietic cells into the circulation, including colony-forming cells and long-term culture-initiating cells. Their numbers are comparable with those in normal BM and are such that a single leukapheresis will usually yield enough cells for hemopoietic reconstitution after myeloablative chemotherapy. during recovery of the hematopoietic system from cytotoxic-induced myelosuppres~ion'~ with or without administration of hematopoietic growth factors.I6-" These "priming" treatments markedly increase the number of circulating hemopoietic progenitors and the primitive cells that generate them,I6 but the optimal priming regimen has not yet been defined, and repeated apheresis procedures are required to obtain enough cells for tran~plantation.'~~'~~'~ Moreover, efficient collection of circulating primitive cells requires a practical method of predicting the time of maximal release in individual patients.
To address these questions, we have compared primitive cells harvested from normal adult BM with the cells from the PB of patients with NHL treated with routine chemotherapy alone or chemotherapy plus granulocyte colonystimulation factor (G-CSF) and assessed their capacity to generate and maintain long-term hematopoiesis in an in vitro transplantation model.
PATIENTS, MATERIALS, AND METHODS

Patients
The release of primitive hematopoietic cells into the PB was studied in patients with NHL enrolled in a phase I11 trial of intensive weekly chemotherapy alone or with G-CSF. Eighty previously untreated patients aged I6 to 7 1 years with histologically documented high-grade NHL (Gel classification) of any stage and performance status were randomized to receive chemotherapy alone or chemotherapy with G-CSF. Fifty patients able and willing to attend for additional sampling underwent detailed blood studies. The study was approved by the District Ethics Committee, and all patients gave informed consent before entry into the trial. Thirteen patients were studied in the group treated with chemotherapy alone. Their median age was 56 years (range 23 to 67 years). There were 10 men and 3 women. BM infiltration was present in two patients at the start of chemotherapy.
Thirty-seven patients were studied in the group treated with chemotherapy plus G-CSF. Their median age was 47 years (range 16 to 67). There were 2 1 men and 16 women. BM involvement was present at the start of chemotherapy in six patients.
Chemotherapy
Patients received treatment with either 11 weeks of VAPEC-B chemotherapy alone or VAPEC-B with G-CSF (Fig I) . For all patients, chemotherapy comprised alternating myelosuppressive (doxorubicin, 35 mum', intravenously [IV] , at weeks 1, 3, 5, 7, 9, and I I; cyclophosphamide, 350 mg/m2, IV at weeks I, 5, and 9; etoposide 100 mg/m2, orally [pol daily for 5 days at weeks 3-7, and I I), and nonmyelosuppressive chemotherapy (vincristine, 1.4 mg/ m2 (maximum 2 mg), IV at weeks 2.4,6,8. and 10 bleomycin. 10 mg/m2, IV at weeks 2, 6, and IO). Patients received prednisolone-EC, 50 mg, orally daily for weeks I to 5 and then 25 mg orally daily for weeks 6 to 1 1. Recombinant human G-CSF(Fi1grastim; Amgen Ltd, Thousand Oaks, CA) was administered as a daily subcutaneous dose of 230 pg/m2 for 13 weeks except for the days preceding and during treatment with doxorubicin, cyclophosphamide, or etop o~i d e .~~ Prophylactic cotrimoxazole, 960 mg, twice a day and ketoconazole, 200 mg, twice a day were administered to all patients throughout treatment. Identical dose modification and antibiotic treatment policies were applied to both groups.
Blood and BM Samples
Normal BM and PB samples were obtained with informed consent from allogeneic transplant donors and normal volunteers. BM specimens for long-term culture ofstromal cells were obtained from allogeneic transplant donors or from diagnostic aspirates in patients with newly diagnosed stages I and I1 Hodgkin's disease. Patients' PB was sampled before chemotherapy and every 2 days during weeks 1 to 3,7 to 9, and I 1 to 14 ofchemotherapy (Fig I) . Throughout day 0 is used to indicate the first day of a chemotherapy cycle. The mono- For personal use only. on October 26, 2017. by guest www.bloodjournal.org From (Flow Labs, Irvine, CA). Cells were counted using an improved Neubauer hemocytometer (Weber Scientific Inrtemational Ltd, Middlesex, UK).
CD34' Cell Population Analysis
An indirect immunofluorescent technique was used to label cells with a CD34+ monoclonal antibody (MoAb) (HPCA-I, BectonDickinson, Mountain View, CA). The percentage of CD34+ cells was estimated on a fluorescent-activated cell sorter (FACS).
Colony-Forming Cell (CFC) Assays
For clonogenic progenitor cell assays, Ficoll-separated PB mononuclear cells were plated in IMDM supplemented with 4 X mol/L glutamine, lo-' mol/L sodium selenite, 2.5 X mol/L alpha-thioglycerol, and 30% FCS, 10% medium conditioned by the bladder carcinoma cell line 5637 (as a source ofgrowth factors), 1% deionized bovine serum albumin (BSA) (Sigma Chemical Co, St Louis, MO), and 2 U of recombinant erythropoietin (Epoetin-alfa) (Cilag Biotech, High Wycombe, UK). Triplicate cultures were set up with a final concentration of IO' mononuclear cell/mL in standard 24-well tissue culture plates (Falcon; Becton Dickinson, MeyIan Cedex, France). The plates were incubated at 37°C in a 5% C02 and 5% O2 in nitrogen atmosphere. Colonies of more than 50 cells at day 14 (CFC) were counted and classified as derived from granulocyte/macrophage (GM-CFC), burst-forming unit-erythroid 
Long-Term Cultures
Two-stage long-term cultures were used.2' To prepare the adherent stromal cell layers, BM cell suspensions from normal donors were depleted of red blood cells (RBC) by gravity sedimentation through 0.1% methylcellulose for 30 minutes at room temperature. After washing, 2 X IO6 cells/mL were inoculated in T25 tissue culture flasks (Falcon) in 10 mL, 10% FCS, 10% horse serum (HS), 5 x IO-' mol/L hydrocortisone sodium succinate (Sigma), and singlestrength IMDM (340 mOsm/kg) supplemented with penicillin and streptomycin. The cultures were gased with 5% C02 in air and incubated at 33°C. At weekly intervals, half of the supernatant was replaced by fresh medium.25 After 4 to 8 weeks of culture, these standard long-term BM cultures were exposed to 15 Gy gamma irradiation from a '37cesium source at a rate of 6.28 cGy/s to ablate endogenous hematopoiesis. The growth medium was removed leaving irradiated stromal layers ready for inoculation of the test hematopoietic cells.
The BM cells used for inoculation on preformed irradiated stromas were obtained after separation with Ficoll (density: 1.077 g/ cm'). Adherent cells were subsequently removed by overnight incubation in plastic flasks containing 2 X IO6 cells per milliliter of IMDM supplemented with 15% FCS at 37°C and 5% COz in air, followed by two incubation periods of 60 minutes. Nonadherent cells (lo6) were seeded onto stroma in a total volume of 10 mL. Culture supernatants were monitored by determining the total number of nucleated cells and the number of CFC in the supernatant at the time of the weekly feeding.
The numbers of CFC lodged in the adherent cell layers were determined at 3 and 6 weeks of culture. The adherent cell layer was washed and treated with 0.25% trypsin at 37°C. After 10 minutes, trypsinization was stopped by adding FCS. The resulting single-cell suspension was washed twice in IMDM with 20% FCS and then adherent cells were depleted by incubation at 2 X lo6 cells/mL in IMDM with 20% FCS at 37°C in 5% C02 in air for 60 minutes. The nonadherent cells were washed once in IMDM containing 2% FCS, counted, and plated to assay for CFC as described above. An inoculum of 5 X IO4 cells were divided between 3 plates and read on day 14.
Statistical Methods
Comparisons among groups were made with standard statistical tests. Results are expressed as median f range except where otherwise stated. Wilcoxon's rank sum test was used for time-dependent variables. The Mann-Whitney unpaired U-test was used for baseline values. The Kruscal-Wallace test was used for multiple paired comparisons between groups.
RESULTS
PB Cell Count
Patients receiving G-CSF throughout the chemotherapy treatment period showed consistently higher total white blood cell (WBC) counts and mononuclear cell fraction recovered after Ficoll separation than patients receiving chemotherapy alone (Fig 1) . The most myelosuppressive treatment was doxorubicin hydrochloride (Adriamycin)/etoposide (AE) administered at cycles 3, 7, and 11, whereas Adriamycinlcyclophosphamide (AC) administered at cycles 1, 5, and 9 was less myelosuppressive. We have shown that G-CSF-treated patients were relatively protected against neutropenia and were more likely to complete treatment on time than controls.24 Because treatments were administered weekly, meaningful nadir and peak values could only be described for the last cycle. After cycle 1 1 chemotherapy in control patients, the median WBC fell from 6. and rose to 35.8 x 109/L (range: 12.8 to 69.7) before discontinuation of G-CSF at median day 15 (range: 7 to 18). After cessation of G-CSF, the counts returned to normal values within 2 to 6 days.
Cell Release Into PB
Mononuclear Cells
Before chemotherapy, the numbers of mononuclear cells and CFC per milliliter of blood were comparable with those of a control group of normal individuals. The mononuclear cell fraction at cycles 7 and 1 1 before commencing AE were not significantly different from baseline pretreatment levels. The peak number of mononuclear cells recovered after Ficoll separation in the G-CSF-treated group doubled after cycle 1 and trebled after cycles 7 and 1 1 of chemotherapy compared with the pretreatment baseline levels (Table 1) . No significant increase was seen in the control group.
Primitive Hematopoietic Cells
An increase in circulating CFC over baseline levels was observed after chemotherapy alone (Table l). After AC at cycle 1, a seven-fold increase in peak colony numbers over pretreatment levels was observed.
Numbers of CFC.
For This contrasts with a 40-fold increase in colony numbers after AE at cycle 11 (Table 1) . CFC release after chemotherapy was markedly enhanced by G-CSF administration (Table I) . At cycle 1, total colony numbers per milliliter of blood increased 56-fold and at cycles 7 and 11, 124-fold and 106-fold, respectively (P < .0005, Kruscal-Wallis test). Colony numbers per milliliter of blood before myelosuppressive chemotherapy at cycles 1, 7, and 1 1 were not significantly different, so there was not an additive effect from 1 1 cycles of chemotherapy.
The chemotherapy-alone patients showed little increase in colony number after cycle 1, whereas the chemotherapy plus G-CSF patients showed increase in colony numbers. After cycle 11, an initial decrease in colony numbers was followed by an exponential increase. The G-CSF patients showed a more rapid recovery and increased to a IO-fold higher peak colony number than the chemotherapy-alone group. Colony numbers remained high for 2 to 3 days before returning toward baseline. Megakaryocyte colony numbers paralleled this release pattern with a median eight-fold (range 1.5 to 73) increase over the baseline at day 0 of cycle 7.
Kinetics of CFC release. Table 2 shows the day of maximal CFC release from day 0 of chemotherapy in each cycle. Although the day of maximum CFC release appears similar after AC and AE, the prolonged administration of AE (5 days v 1 day for AC) conceals the finding that CFC release occurs relatively earlier after the more myelosuppressive AE treatment. This applied to both groups of patients. Those receiving chemotherapy plus G-CSF achieved maximal CFC release earlier than those receiving chemotherapy alone. In individual patients, the day of maximal progenitor release was reproducible after the same myelosuppressive stimulus unless the patient became septic.
In individuals who developed sepsis during treatment, progenitor release was delayed until resolution of the infection and the numbers of colonies remained at levels seen in patients receiving chemotherapy alone. In these patients, release was normal in subsequent cycles. Progenitor release was also lower in patients with poor performance status at presentation (data not shown).
The release ofprimitive hemopoietic cells parallels the WBC counts and mononuclear cell counts but precedes them (Fig 2) . In patients receiving VAPEC-B and G-CSF, the nadir of CFC after cycle 11 (AE) falls on median day 7 (range: 6 to 9) and the WBC count nadir on median day 9 (range: 4 to 1 I). The peak release of CFC occurs on median day 1 1 (range: 9 to 15) and the WBC peak on median day 15 (range: 7 to 18). The WBC decreased rapidly after stopping G-CSF, so that the last day of G-CSF administration was always the day of peak WBC. G-CSF treatment was continued beyond the CFC peak in 19 of the 30 G-CSF-treated patients. Progenitor cells peaked and fell despite a continuing increase in Prediction of maximal CFCrelease. Temporal relation between total WBC count and PB progenitor release after myelosuppressive chemotherapy (AE) in eight patients in whom G-CSF was continued past the colony peak in cycle l l. In all patients, the G-CSF was started 24 hours after the last chemotherapy (day 6) and was discontinued at the WBC count peak. Peak progenitor release coincides with the early phase of the exponential increase in WBC count.
For personal use only. on October 26, 2017. by guest www.bloodjournal.org From 2244 PETTENGELL ET AL WBC counts (Fig 2) . No patient achieved a WBC peak before the peak in CFC. In all patients, peak progenitor release coincided with the exponential increase in the WBC. Therefore, maximal hematopoietic progenitor release was predicted by the early exponential phase of increasing WBC. Progenitor numbers remained high for several days in some patients but fell rapidly in others.
At 
CD34+ cell analysis.
Generation of Hematopoiesis in Long-term Culture
Normal Controls
PB mononuclear cells from normal individuals, seeded on irradiated BM stroma were unable to generate long-term hematopoiesis in two-stage long-term cultures. Numbers of nonadherent cells per culture fell rapidly to IO5 or less for the duration of the culture. Very few CFC were detected throughout the culture period, and in all cases their number steadily declined to 10 or less after only 1 week of culture (Fig 3) . No CFC were detected in the adherent cell layers harvested at weeks 3 to 6 of culture (Fig 4) .
Preceding Chemotherapy
PB mononuclear cells collected both pretherapy and before the administration of AE at cycles 7 and l l from patients receiving chemotherapy alone and chemotherapy with G-CSF were unable to sustain hematopoiesis, giving similar values to normal controls (Figs 3 and 6 ).
Postchemotherapy Alone
Cultures were initiated from cells obtained at the time of peak progenitor release after cycles 1 and 1 1 of the VAPEC-B chemotherapy regimen. The numbers of CFC measured in the supernatant or in the adherent layer (Fig 4) were comparable with those obtained when BM cells were seeded.
Postchemotherapy and G-CSF
Mononuclear cells collected at the time of peak progenitor release after chemotherapy cycles I , 7, and 1 1 from patients treated with VAPEC-B and G-CSF were found to have an in vitro repopulating capacity similar to control cultures of adherent cell-depleted BM from normal individuals when cultured on irradiated stroma. These cultures plateau above the initial inoculum density from weeks 3-6 to the termination of the cultures (Fig 3) .
The pattern is similar in colony numbers in the adherent layer measured at weeks 3 and 6 with a significant increase in all groups including cycle 1 over baseline values (P < .0005, Mann-Whitney U-test, unpaired; Fig 4) . The numbers of CFC in the adherent layer are 300-500-fold increased over those observed in cultures of normal peripheral blood and up to a threefold increase relative to normal BM. This represents a 50-to 100-fold enrichment of primitive hematopoietic cells over those primed by chemotherapy alone.
A comparison of the capacity to generate hematopoiesis between normal BM mononuclear cells and PB mononuclear cells primed by chemotherapy plus G-CSF is shown in For 
Sustained Hematopoiesis
A comparison of the area under the curve (AUC) for the 6
weeks from the initiation of the long-term culture for cell numbers per culture showed no statistical difference between PB from normal individuals, pretreatment PB, and PB mononuclear cells collected before treatment with AE in patients receiving chemotherapy alone or chemotherapy with G-CSF. Neither was there a significant difference when the AUC for total colony numbers in these cultures were compared. However, there was a trend to higher colony numbers at day 0 of cycles 7 and 11 in the group receiving both chemotherapy and G-CSF (Fig 6) .
The AUC for nonadherent cell numbers per flask in cultures seeded after cycle l l in patients receiving chemotherapy alone were significantly increased over control PB ( P = .OO 1, Kruscal-Wallis test) and were not significantly different from BM (Fig 6) .
The AUC for mononuclear cells and colonies per flask in the nonadherent layer in long-term cultures from normal BM and PB of patients receiving chemotherapy with G-CSF at cycle 7, and cycle 1 I cultures were significantly increased over control PB ( P < .0005, Mann-Whitney U-test, unpaired) but were not significantly different from each other (Fig 6) .
DISCUSSION
PB offers a source of hematopoietic stem cells for transplantation in patients without an allogeneic BM donor. In humans, more GM-CFC/kg body weight are considered necessary for successful engraftment with PB cells than with BM.26,2' Consistent with this, we have shown that PB mononuclear cells from normal controls and patients with NHL before chemotherapy contain few CD34' cells (0.18%) and are unable to initiate hematopoiesis in an in vitro model of transplantation-the two-stage long-term culture assay.
In contrast, after chemotherapy and G-CSF, CD34+ cells increased to a median of 4% and PB mononuclear cells had a repopulating capacity at least equal to BM. Indeed, the delayed onset of GM-CFC production and mature cell out- put in the two-stage long-term cultures initiated with mobilized PB mononuclear cells (Fig 3) and the magnitude and duration of generated progenitor cells (Fig 5) suggest that the inoculum contains relatively more primitive cells than normal blood or BM. This is supported by finding that more clonogenic cells are present in the adherent cell layer from cultures initiated with PB mononuclear cells obtained after treatment with chemotherapy and G-CSF than BM or those primed with chemotherapy alone (Fig 4) . Previous studies have used seriously high doses of myelosuppressive agents to mobilize progenitors into the PB with or without hematopoietic growth factor^.'^^^'*^^ We have shown that patients with high-grade NHL receiving routine outpatient induction chemotherapy with VAPEC-B achieved a modest increase in PB progenitor cells after chemotherapy alone. This increase was markedly enhanced by treatment with G-CSF after chemotherapy.
-
Weeks in Culture
Like other^,'^,^^ we have found that there is greater mobilization of progenitors into the circulation when a more myelosuppressive stimulus is used: AE at cycles 7 and 11 was more myelosuppressive and a better priming treatment than AC at cycle 1. Interestingly, a low-nadir absolute neutrophil count (ANC) is not a prerequisite for the release of primitive cells. Patients receiving chemotherapy with G-CSF were both protected from neutropenia and had enhanced primitive hemopoietic cell release. Corticosteroids have been suggested to contribute to hematopoietic progenitor release, but this has been controlled for in this study, as prednisolone, 25 mg, daily was administered to both groups.
To date, multiple apheresis procedures have been required to obtain enough primitive blood cells for transplantation even in patients with little prior treatment.20,23,30 This five patients taken before to cy-
has resulted in considerable patient morbidity, expense, and delays in initiating treatment that could prove harmful to patients with rapidly growing tumors. The 400-fold increase in GM-CFC after priming with VAPEC-B and G-CSF (Table l ) indicates that it will usually be possible to harvest sufficient PB stem cells at a single apheresis and that the toxicity of more myelosuppressive chemotherapy is not justified. A minimum of 5 X lo4 GM-CFC/kg body weight are recommended for BM transplantation. Based on the GM-CFC yields from patients primed with chemotherapy and G-CSF in this study, we predict that mononuclear cells from 5 mL/kg body weight PB will be sufficient for successful engraftment. These results have led us to use G-CSF priming for apheresis after AE in 7-cycle VAPEC-B in 13 patients with high-grade NHL of poor progn~sis.~' In each case, adequate numbers of PB progenitor cells for transplantation were obtained at a single apheresis. Median (range) yields were mononuclear cells 3.8 x 108/kg (0.2 to 9.7);
GM-CFC 8.3 X 105/kg (5.2 to 22.0); CD34' cells 2.8 X 107/kg (6.8 to 41.0). We have also successfully used this method to mobilize hematopoietic progenitor cells for transplantation in heavily pretreated patients with acute lymphoblastic leukemia and relapsed Hodgkin's di~ease.'~ Despite variability between patients, we have found that the magnitude and timing ofprimitive cell release are reproducible following an identical stimulus in individual patients unless infection supervenes. It is possible to predict the time of peak release and optimize cell collection (Fig 2) . In any individual, the WBC count was as useful for predicting the day of peak primitive cell release as CFU-GM numbers. In all patients, the increase in circulating WBC after myelosuppressive chemotherapy with or without G-CSF parallels the release of primitive hematopoietic cells but lags (Fig 2) . The optimal time for primitive blood cell collection is when the WBC is increasingexponentially after the chemotherapy-induced nadir. In patients receiving VAPEC-B and G-CSF, this occurs when the WBC is
The advantages of early collection, before irreversible cytotoxic damage to BM tissue has occurred, must be weighed against the disadvantages, such as increased risk of malignant ~o n t a m i n a t i o n .~~ Using VAPEC-B chemotherapy, there is no difference in primitive blood cell release at cycle 7 over cycle 1 1 nor in the ability of these cells to initiate and sustain long-term hematopoiesis in vitro, which indicates that in the short term there is no measurable damage to the BM.
There are many descriptive reports of PB stem cell transplantation in humans, but the source of the cells effecting long-term engraftment has not been determined, and therefore it is unclear if long-term hematopoiesis originates from the graft or from the surviving host cells. Studies of sex-mismatched syngeneic transplants in mice show that the same minimum number of cells are required for in vivo engraftment using PB mononuclear cells from mice treated with G-CSF or normal BM. 34 This study also showed that the transplanted PB cells are able to reconstitute long-term hemopoiesis of donor origin. 34 In our in vitro transplantation model, primed human PB mononuclear cells are similarly comparable with BM indicating that they also have the potential to contribute to long-term hematopoiesis. To establish this unequivocally will require gene-marking studies.35 Therefore, transplantation with primitive hematopoietic cells from the PB after myeloablative therapy could be a safe alternative to BM.
In conclusion, we have shown that chemotherapy with G-CSF is a better priming regimen than chemotherapy alone in patients with high-grade NHL. VAPEC-B and G-CSF increase the number of circulating progenitors to levels comparable with normal BM. Therefore, it is feasible to collect sufficient cells for autologous transplantation at a single apheresis and without delay or disruption to routine chemotherapy. The blood contains both committed progenitors and cells with an in vitro BM-repopulating capacity (long-term culture-initiating cells). The release of primitive cells parallels the increase in WBC with a set lag. Therefore, an increasing WBC can be used as a guide to when to harvest.
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